Just 6 weeks after striking a $2.3 billion deal to develop off-the-shelf cell therapies with Shoreline Biosciences, Gilead sub Kite Pharma has bounced back with another alliance — this time centered on chimeric antigen receptor (CAR)-engineered invariant natural killer T (CAR-iNKT) cells using Appia Bio’s platform...
Gilead’s Kite jumps back to the bargaining table to forge $875M pact with a newly-emerged upstart on next-gen cell therapies
